Harrow (HROW) Equity Income (2018 - 2019)
Harrow's (HROW) quarterly Equity Income came in at $400000.0 in Q3 2019, up 53.26% quarter-over-quarter from $261000.0 in Q2 2019.
Harrow (HROW) Equity Income (2018 - 2019) Analysis & Trends
Harrow's Equity Income history runs 2 years deep, the most recent figure standing at $400000.0 for Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.43 Bn | 1.34 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 400,000.00 |
| Jun 30, 2019 | 261,000.00 |
| Jun 30, 2018 | 102,000.00 |